Discover
INZY
Inozyme Pharma, Inc.
4.00
undefined x undefined
undefined x undefined
bid
ask
+
4.00
0.00%
07:00 PM
| Ytd | 44.40% | |
| 1y | -10.31% |
day range
52 week range
| Open | Prev Close | Low | High | Mkt Cap | N/A | ||||
| Vol | 0.00 | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -1.86 |
| Beta | 1.54 | Short Ratio | 7.59 | Inst. Own | 98.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 19.56 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-05 | 2024-09 | -0.44 | -0.39 | 0.05 | 11.36% |
| 2024-08-06 | 2024-06 | -0.37 | -0.44 | -0.07 | -18.92% |
| 2024-08-06 | 2024-06 | -0.37 | N/A | N/A | N/A |
| 2024-05-07 | 2024-03 | -0.35 | -0.38 | -0.03 | -8.57% |
| 2024-05-07 | 2024-03 | -0.35 | N/A | N/A | N/A |
| 2024-03-12 | 2023-12 | -0.31 | -0.35 | -0.04 | -12.90% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-06 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-06 | Needham | Upgrade | Buy | Buy |
| 2024-10-25 | Needham | Upgrade | Buy | Buy |
| 2024-10-25 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-09-30 | Wedbush | Upgrade | Outperform | Outperform |
| 2024-09-12 | Stifel | Upgrade | Buy |
Profile
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-03-30 | BOLTE AXEL | Director | 266.70K | Stock Award(Grant) |
| 2023-07-31 | HOPFNER ROBERT LORNE | Director | 0.00 | Purchase |
| 2023-07-31 | PIVOTAL BIOVENTURE PARTNERS FUND I, L.P. | Unknown | 0.00 | Purchase |
| 2023-09-28 | SUBRAMANIAN SANJAY | Chief Financial Officer | 30.40K | Stock Award(Grant) |
| 2024-09-29 | TRECO DOUGLAS A | Chief Executive Officer | 22.38K | Stock Award(Grant) |
| 2024-09-29 | WINTON MATTHEW | Chief Operating Officer | 4.90K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Adage Capital Partners GP L.L.C. | 5.67M | 17.08M | 8.83% |
| 2024-09-29 | Pivotal bioVenture Partners Investment Advisor, LLC | 4.49M | 13.53M | 7.00% |
| 2024-09-29 | Sofinnova Investments, Inc. | 4.28M | 12.88M | 6.66% |
| 2024-09-29 | Eventide Asset Management LLC | 4.13M | 12.44M | 6.44% |
| 2024-09-29 | Rock Springs Capital Management, LP | 3.80M | 11.45M | 5.92% |
| 2024-09-29 | Blackrock Inc. | 3.49M | 10.51M | 5.43% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund | 4.13M | 12.44M | 6.44% |
| 2024-10-30 | Fidelity Select Portfolios - Biotechnology | 2.13M | 6.41M | 3.32% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.56M | 4.69M | 2.43% |
| 2024-10-30 | iShares Russell 2000 ETF | 1.33M | 4.01M | 2.07% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 679.65K | 2.05M | 1.06% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 527.75K | 1.59M | 0.82% |